Critical Review: Boiron (BOIRF) & Its Rivals

Boiron (OTCMKTS:BOIRF – Get Free Report) is one of 252 public companies in the “Drug Manufacturers – Specialty & Generic” industry, but how does it compare to its rivals? We will compare Boiron to related businesses based on the strength of its earnings, valuation, risk, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Boiron and its rivals’ net margins, return on equity and return on assets.

Get Boiron alerts:

Valuation and Earnings

This table compares Boiron and its rivals gross revenue, earnings per share (EPS) and valuation.

Boiron’s rivals have higher revenue, but lower earnings than Boiron. Boiron is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Dividends

Boiron pays an annual dividend of $1.20 per share and has a dividend yield of 2.2%. Boiron pays out 30.4% of its earnings in the form of a dividend. As a group, “Drug Manufacturers – Specialty & Generic” companies pay a dividend yield of 4.7% and pay out 37.9% of their earnings in the form of a dividend.

Institutional & Insider Ownership

9.7% of Boiron shares are held by institutional investors. Comparatively, 21.0% of shares of all “Drug Manufacturers – Specialty & Generic” companies are held by institutional investors. 26.4% of shares of all “Drug Manufacturers – Specialty & Generic” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Boiron and its rivals, as reported by MarketBeat.com.

As a group, “Drug Manufacturers – Specialty & Generic” companies have a potential upside of 56.24%. Given Boiron’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Boiron has less favorable growth aspects than its rivals.

Summary

Boiron rivals beat Boiron on 9 of the 13 factors compared.

Boiron Company Profile

(Get Free Report)

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Receive News & Ratings for Boiron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boiron and related companies with MarketBeat.com's FREE daily email newsletter.